Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

Dec 11, 2021
Source URL: https://www.novartis.com/us-en/news/media-releases/novartis-kymriah-demonstrates-strong-responses-high-risk-patients-relapsed-or-refractory-follicular-lymphoma-extended-study-follow-0

List of links present in page